Overview
Smart money at a glance
Filings to Oct 12, 2026Mixed: insiders sold $150K and bought $173K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$23K netMixed
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
Market overview
Fundamentals Aug 15- 52-wk high
- $0.27
- 52-wk low
- $0.03
- Beta
- 0.42
- Profit margin
- -8.0%
- Op margin
- -4.4%
- ROE
- -4132.0%
What do analysts expect?
No analyst estimates.
Questions about TOIIW filings
Are insiders buying or selling The Oncology Institute Inc (TOIIW) stock?
Mixed: insiders sold $150K and bought $173K of TOIIW stock on the open market in the 90 days to Oct 12, 2026, according to SEC Form 4 filings. $150K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Chernett, Jorey (10% owner), who bought $173K. The latest filing was on Aug 17, 2026.
Which members of Congress have traded TOIIW recently?
None. No member of Congress disclosed a TOIIW trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this TOIIW smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
1 fund holds a position and insiders have been net buying.
What insiders are doing
Buys (2)
- CJ
Chernett Jorey
$78K
bought
- CJ
Chernett Jorey
$95K
bought
Sells (1)
- PY
Podnos Yale
$150K
sold
How top traders are positioned
No tracked top-trader positions in TOIIW right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No earnings history.
What the street expects next
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -8.0%
Valuation
Quality
- Operating margin-4.4%
- ROE-4132.0%
- ROA-12.3%
Growth
- Beta0.42
Technicals
Price structure
Market data unavailable.